SCHEMBL6859346

SCHEMBL6859346

CCCC(C)NC(=O)CS

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.51
KMT2A Q03164 3/20 0.49
LMNA P02545 2/20 0.44
THRB P10828 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
ALDH1A1 P00352 3/20 0.43
HPGD P15428 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
MEN1 O00255 1/20 0.39
FAAH O00519 1/20 0.39
MAPK1 P28482 1/20 0.39
PKM P14618 1/20 0.39
GAA P10253 1/20 0.38
KDM4E B2RXH2 1/20 0.38
KCNK3 O14649 1/20 0.36
CNR2 P34972 1/20 0.36
BLM P54132 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8847485 0.82 POLB (0.55) POLBKMT2ALMNATHRBSMN1; SMN2
SCHEMBL27391834 0.82
SCHEMBL16298854 0.82 POLB (0.55) POLBKMT2ALMNATHRBSMN1; SMN2
SCHEMBL13416265 0.82 POLB (0.55) POLBKMT2ALMNATHRBSMN1; SMN2
SCHEMBL8848209 0.82 POLB (0.55) POLBKMT2ALMNATHRBSMN1; SMN2
SCHEMBL6010086 0.82
SCHEMBL5141993 0.80 POLB (0.53) POLBKMT2ALMNATHRBSMN1; SMN2
SCHEMBL5143891 0.80 POLB (0.53) POLBKMT2ALMNATHRBSMN1; SMN2
SCHEMBL24235744 0.78 POLB (0.51) POLBKMT2ALMNATHRBSMN1; SMN2
SCHEMBL21377157 0.78 POLB (0.51) POLBKMT2ALMNATHRBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10605810-B2 Pincers comprising antibody and aptamer conjugated via a linker which binds to the same target material and use thereof UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY (KR) 2020-03-31 US disclosed
US-20170028070-A1 PINCERS COMPRISING ANTIBODY AND APTAMER CONJUGATED VIA A LINKER WHICH BINDS TO THE SAME TARGET MATERIAL AND USE THEREOF UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY (KR) 2017-02-02 US disclosed
US-6790971-B1 AMIDE OR CARBAMATE FUNCTION AT 11 BETA-POSITION; CLAIMED 3-ONE-DIENE INTERMEDIATE HAS HYDROXYMETHYLALKYL GROUP ON 11 POSITION; ANTIPROGESTOMIMETIC; HORMONE-DEPENDENT TUMORS; ANIMAL HUSBANDRY AVENTIS PHARMA S.A. (FR) 2004-09-14 US disclosed
EP-0471612-B1 New steroids having an amide substituted group in the 11-beta position, their preparation, their use as medicines and pharmaceutical composition thereof ROUSSEL UCLAF (FR) 1998-01-28 EP disclosed
US-5707982-A ANTITUMOR ROUSSEL UCLAF (FR) 1998-01-13 US disclosed
EP-0471612-A2 New steroids having an amide substituted group in the 11-beta position, their preparation, their use as medicines and pharmaceutical composition thereof ROUSSEL UCLAF (FR) 1992-02-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170028070-A1 PINCERS COMPRISING ANTIBODY AND APTAMER CONJUGATED VIA A LINKER WHICH BINDS TO THE SAME TARGET MATERIAL AND USE THEREOF ILK, PAICS, AURKC POLB 2296/4885KMT2A 1147/4885LMNA 124/4885
US-10605810-B2 Pincers comprising antibody and aptamer conjugated via a linker which binds to the same target material and use thereof ILK, PAICS, AURKC POLB 2296/4885KMT2A 1147/4885LMNA 124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.